Development
EquiCord has carried out an exhaustive research and development process to demonstrate the quality, safety and efficacy of Umbilical Cord Mesenchymal Stem Cells
Clinical development
Safety and efficacy of MSCs in equine OA
Preclinical
Proof of Concept
Assay on the safety of intra-articular application of allogenic mesenchymal stem cells from equine umbilical cord in healthy horses
Phase I
Single and repeated dose
*VICH GL9
Immunogenicity clinical trial: Cellular and Humoral response
*VICH GL9
Inmunogenicity clinical trial: Cellular and Humoral response
Phase II
Proof of concept for determining safety and efficacy in intra-articular administration of the doses selected of allogenic umbilical cord mesenchymal stem cells in horses with degenerative joint disease
*VICH GL9
Phase III
Determination of safety and efficacy in intra-articular administration of allogenic mesenchymal stem cells from umbilical cord in horses with degenerative joint disease
*VICH GL9
Efficacy and safety study of allogenic mesenchymal stem cells from umbilical cord for the treatment of clinical symptomatology associated with mild to moderate degenerative joint disease (OA) in horses under field conditions
*VICH GL9
Phase IV
Long term follow up study:
Efficacy and safety study 2 years after HorStem administration
Post-authorization Survey Study about HorStem´s Safety and Efficacy in 800 horses
*VICH GL9
Clinical results
Clinical trials designed and conducted by our scientific team have shown that HorStem is effective in reducing lameness in horses with mild to moderate degenerative joint disease.
All of our clinical trials have been carried out following the international standards for the homogenisation of clinical trials VICH GL9 and after authorisation from the Spanish Agency of Medicines and Health Products (AEMPS).
72% of the treated horses reduced their degree of lameness to absence of lameness or inconsistent lameness
Likewise, long-term studies have shown that the efficacy of HorStem is very long-term, showing that 83% of the animals did not relapse in their symptoms or need additional medication 12 months after the application of HorStem.
